Quantitative structure-activity relationship studies of TIBO derivatives using support vector machines

SAR and QSAR in Environmental Research

Volumn 21, Issue 3, 2010, Pages 231-246

  Darnag, R ^a   Schmitzer, A ^b   Belmiloud, Y ^c   Villemin, D ^d   Jarid, A ^a   Chait, A ^a   Mazouz, E ^a   Cherqaoui, D ^a  

^a FACULTÉ DES SCIENCES SEMLALIA   (Morocco)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^d 6 Bd du Maréchal Juin   (France)

Author keywords

Anti HIV; MLR; Neural network; QSAR; Support vector machine; TIBO

Indexed keywords

COMPUTATIONAL CHEMISTRY; LINEAR REGRESSION; MOLECULAR GRAPHICS; RADIAL BASIS FUNCTION NETWORKS; STRUCTURES (BUILT OBJECTS);

ANTI-HIV; ANTI-HIV ACTIVITY; MLR; MOLECULAR DESCRIPTORS; NEURAL-NETWORKS; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDIES; SUPPORT VECTOR MACHINE TECHNIQUES; SUPPORT VECTORS MACHINE; TIBO;

SUPPORT VECTOR MACHINES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77953556339     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629361003770977     Document Type: Article

References (42)

1. A. Jacobo-Molina and E. Arnold, HIV reverse transcriptase structure-function relationships, Biochemistry 30 (1991), pp. 6351-6632.
2. E. De Clercq, Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development, Med. Chem. Rev. 16 (1996), pp. 125-157.
3. E. De Clercq, Antiviral therapy for human immunodeficiency virus infections, Clin. Microbiol. Rev. 8 (1995), pp. 200-239.
4. E. De Clercq, What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections, Rev. Med. Virol. 6 (1996), pp. 97-117.
5. J. Balzarini, A. Karlsson, M.J. Perez-Perez, M.J. Camarasa, and E. De Clercq, Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus, Virology 196 (1993), pp. 576-585.
6. M.B. Vasudevachari, C. Battista, H.C. Lane, M.C. Psallidopoulos, B. Zhao, J. Cook, J.R. Palmer, D.L. Romero, W.G. Tarpley, and N.P. Salzman, Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors, Virology 190 (1992), pp. 269-277.
7. R. Pauwels, K. Andries, J. Desmyter, D. Schols, M.J. Kukla, H.J. Breslin, A. Raeymaechers, J.V. Gelder, R. Woestenborgs, J. Heykants, K. Schellekens, M.A.C. Janssen, E. DeClercq, and P.A.J. Janssen, Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivative, Nature 343 (1990), pp. 470-474.
8. C. Hansch, D. Hoekman, and H. Gao, Comparative QSAR: Toward a deeper understanding of chemicobiological interactions, Chem. Rev. 96 (1996), pp. 1045-1075.
9. M. Karelson, V.S. Lobanov, and A.R. Katritzky, Quantum-chemical descriptors in QSAR/ QSPR Studies, Chem. Rev. 96 (1996), pp. 1027-1043.
10. R. Garg, S.P. Gupta, H. Gao, M.S. Babu, and A.K. Debnath, Comparative quantitative structure-activity relationship studies on anti-HIV drugs, Chem. Rev. 99 (1999), pp. 3525-3601.
11. M.A. Sattwa and R. Kunal, Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives, Eur. J. Med. Chem. 44(4) (2009), pp. 1509-1524.
12. N.S. Sapre, S. Gupta, N. Pancholi, and N. Sapre, A group center overlap based approach for «3D QSAR» studies on TIBO derivatives, J. Comput. Chem. 30(6) (2009), pp. 922-933.
13. J. Zupan and J. Gasteiger, Neural Networks for Chemists: An Introduction, Wiley-VCH, Weinheim, 1993.
14. I. Guyon, J. Weston, S. Barnhill, and V. Vapnik, Gene selection for cancer classification using support vector machines, Mach. Learn. 46 (2002), pp. 389-422.
15. H.X. Liu, R.S. Zhang, F. Luan, X.J. Yao, M.C. Liu, Z.D. Hu, and B.T. Fan, Diagnosing breast cancer based on support vector machines, J. Chem. Inf. Comput. Sci. 43 (2003), pp. 900-907.
16. Y.D. Cai, X.J. Liu, X.B. Xu, and K.C. Chou, Diagnosing breast cancer based on support vector machines, J. Comput. Chem. 23 (2002), pp. 267-274.
17. S.J. Hua and Z.R. Sun, A novel method of protein secondary structure prediction with high segment overlap measure: Support vector machine approach, J. Mol. Biol. 308 (2001), pp. 397-407.
18. U. Norinder, Support vector machine models in drug design: applications to drug transport processes and QSAR using simplex optimisations and variable selection, Neurocomputing 55 (2003), pp. 337-346.
19. R. Hu, J.P. Doucet, M. Delamar, and R. Zhang, QSAR models for 2-amino-6-arylsulfonylben- zonitriles and congeners HIV-1 reverse transcriptase inhibitors based on linear and nonlinear regression methods, Eur. J. Med. Chem. 44 (2009), pp. 2158-2171.
20. R. Darnag, A. Schmitzer, Y. Belmiloud, D. Villemin, A. Jarid, A. Chait, M. Seyagh, and D. Cherqaoui, QSAR studies of HEPT derivatives using support vector machines, QSAR. Comb. Sci. 28 (2009), pp. 709-718.
21. M. Pavan, T.I. Netzeva, and A.P. Worth, Validation of a QSAR model for acute toxicity, SAR QSAR Environ. Res. 17 (2006), pp. 147-171.
22. S. Hannongbua, P. Pungpo, J. Limtrakul, and P. Wolschann, Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatives HIV-1 reverse transcriptase inhibitors, J. Comput. Aided Mol. Design 7 (1999), pp. 2283-2292.
23. S.P. Gupta and R. Garg, Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase, J. Enzyme. Inhib. 11 (1996), pp. 23-32.
24. S. Hannongbua, P. Pungpo, J. Limtrakul, and P.J. Wolschann, Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors, Comput. Aided Mol. Design. 13 (1999), pp. 563-577.
25. Y. Belmiloud, Theoretical modeling and QSAR studies of TIBO derivatives, PhD thesis, Science and Technology University of Alger, 2009.
26. D. Cherqaoui and D. Villemin, Use of a neural network to determine boiling point of alkanes, J. Chem. Soc. Faraday. Trans. 90 (1994), pp. 97-102.
27. J.A. Freeman and D.M. Skapura, Neural Networks Algorithms, Applications, and programming Techniques, Addition-Wesley Publishing Company, Reading, 1991.
28. V.N. Vapnik, Statistical Learning Theory, John Wiley & Sons, New York, 1998.
29. N. Cristianini and J. Shawe-Taylor, An Introduction to Support Vector Machine, Cambridge University Press, Cambridge, UK, 2000.
30. B. Scholkopf and A. Smola, Learning with Kernels, MIT Press, Cambridge MA, 2002.
31. C.C. Chang, and C.J. Lin, LIBSVM-A Library for support vector machine. Available at http:// www/csie.edu/tw/cjlin/libs/libsvm.
32. S. So and G. Richards, Application of neural networks: Quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl) pyrimidines as DHFR Inhibitors, J. Med. Chem. 35 (1992), pp. 3201-3207.
33. T.A. Andrea and H. Kalayeh, Application of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors, J. Med. Chem. 34 (1991), pp. 2824-2836.
34. H.T. Lin and C.J. Lin, A Study on Sigmoid Kernels for SVM and the Training of non-PSD Kernels by SMO-type Methods, National Taiwan University, 2004. Available at http://www.csie.ntu.edu.tw/ cjlin/papers/tanh.pdf.
35. W.J. Wang, Z.B. Xu, W.Z. Lu, and X.Y. Zhang, Determination of the spread parameter in the Gaussian kernel for classification and regression, Neurocomputing 55 (2003), pp. 643-663.
36. A. Tropsha, P. Gramatica, and V.K. Gombar, The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models, Quant. Struct- Act. Relat. 22 (2003), pp. 1-9.
37. L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification and regression-based QSARs, Environ. Health. Perspect. 111 (2003), pp. 1361-1375.
38. P. Gramatica, Principles of QSAR models validation: internal and external, QSAR. Comb. Sci. 26 (2007), pp. 694-701.
39. D. Cherqaoui, M. Esseffar, D. Villemin, J.M. Cense, M. Chastrette, and D Zakarya, Structure musk odour relationships studies of tetralin and indan compounds using neural networks, New. J. Chem. 22 (1998), pp. 839-843.
40. E. De Clercq, Perspective of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection, Il Farmaco. 54 (1999), pp. 26-45.
41. L. Douali, D. Villemin, and D. Cherqaoui, Exploring QSAR of non-nucleoside reverse transcriptase inhibitors by neural networks: TIBO derivatives, Int. J. Mol. Sci. 5 (2004), pp. 8-55.
42. R. Esnouf, J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors, Nat. Struct. Biol. 2 (1995), pp. 303-308.